U.S. markets open in 7 hours 5 minutes

ResMed Inc. (R1MD34.SA)

Sao Paolo - Sao Paolo Delayed Price. Currency in BRL
Add to watchlist
304.000.00 (0.00%)
At close: 11:47AM BRT
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close304.00
Bid296.10 x N/A
Ask0.00 x N/A
Day's Range0.00 - 0.00
52 Week Range
Avg. Volume33
Market Cap177.723B
Beta (5Y Monthly)0.28
PE Ratio (TTM)77.49
EPS (TTM)3.92
Earnings DateN/A
Forward Dividend & Yield2.09 (0.69%)
Ex-Dividend DateMay 12, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • ResMed (RMD) Hits a New 52-Week High: What's Driving It?

      ResMed (RMD) Hits a New 52-Week High: What's Driving It?

      Investors are optimistic about ResMed (RMD) on solid digital health growth potential along with rising demand for masks and other accessories.

    • Why ResMed Stock Exploded Higher This Week
      Motley Fool

      Why ResMed Stock Exploded Higher This Week

      Through Thursday's close, shares of the medical equipment company ResMed (NYSE: RMD) were up by a healthy 10% so far this week. ResMed's stock is marching higher this week in response to Koninklijke Philips' (NYSE: PHG) decision to voluntarily recall approximately 3.5 million ventilation devices for treating sleep apnea. Philips is recalling the devices over the use of a polyester-based polyurethane (PE-PUR) sound abatement foam that could be toxic if inhaled or ingested.

    • 5 Reasons Why ResMed Gets Downgrade From BofA Securities

      5 Reasons Why ResMed Gets Downgrade From BofA Securities

      Although ResMed Inc’s (NYSE: RMD) long-term outlook is positive, the market seems to have over-reacted to rival Koninklijke Philips NV’s (NYSE: PHG) recall notification of certain sleep and respiratory care devices for the U.S., according to BofA Securities. The ResMed Analyst: Lyanne Harrison downgraded the rating for ResMed from Neutral to Underperform, while raising the price target from $216 to $221. The ResMed Thesis: Although the company is poised to benefit from Philips’s recall, the magn